once monthly glp 1 agonist Dosage of GLP-1 analogues Once Monthly GLP-1 receptor agonist

Description

NAD(+) metabolism and the control of energy homeostasis: a balancing act between mitochondria and the nucleus

Tirzepatide is approved as Mounjaro for T2D and as Zepbound for chronic weight management and, notably by the FDA, for treatment of moderate to severe OSA in adults with obesity

Reductions in risk observed for several other cancer types including upper gastrointestinal cancer (HR = 0.6

At 12 months, the percentage of weight loss was numerically but not statistically significant

Additionally, GLP-1 agonists suppress glucagon secretion from pancreatic alpha cells, slow gastric emptying, and promote satiety through central nervous system effects, contributing to weight loss in many patients